Dendreon: landmark cancer vaccine approval but high costs may hinder uptake
7th May 2010 19:30
Having been approved by the FDA in castration-resistant prostate cancer (press release), Dendreon's Provenge represents the first therapeutic cancer vaccine to reach the market (click here for related reports). This is a significant step forward: the current standard of care is Taxotere-based chemotherapy, which is associated with significant toxicity. However, it remains to be seen how frequently Provenge is used.
Provenge (sipuleucel-T; Dendreon) is composed of autologous peripheral blood mononuclear cells, including antigen-presenting cells that have been activated during culture with a recombinant human protein, PAP-GM-CSF. PAP-GM-CSF consists of prostatic acid phosphatase (PAP), an antigen expressed on approximately 95% of prostate tumor cells, linked to granulocyte-macrophage colony-stimulating factor (GM-CSF), an immune cell activator. Upon administration, the PAP-activated cells cause activation of T-cells and other immune system components to recognize the target antigen and destroy prostate tumor cells.
Manufacture of Provenge requires collection of antigen-presenting cells from individual patients, via leukapheresis, a blood collection process used to isolate white blood cells. The cells are then transported to the Dendreon manufacturing facility, presumably in cold storage, where co-culture with a PAP-containing recombinant fusion protein occurs. Manufacture of Provenge takes approximately two days, after which the vaccine is delivered to the physician's office for infusion into the patient. This entire process is carried out three times over the course of a four-week period, in order to provide three vaccinations to each patient.
Provenge has had a troubled development history to date. Dendreon initially filed a Biologics License Application (BLA) in January 2007 on the basis of Phase III D9901 study results, which showed an improvement in overall survival but failed to meet its primary endpoint of time to progression. The FDA issued an approvable letter in May 2007, requesting additional clinical data. This was met with controversy from the public; indeed, prostate cancer patient group Care to Live filed a lawsuit against the FDA, demanding that Provenge be approved.
Following this, the FDA stated that it would accept interim or final data from the ongoing Phase III IMPACT study to amend Provenge's BLA. Positive results were announced in April 2009, showing that Provenge conferred a 4.1 month survival benefit over placebo in asymptomatic or minimally symptomatic metastatic CRPC, thus meeting the study's primary endpoint. This made Provenge the first therapeutic cancer vaccine to demonstrate an improvement in overall survival for metastatic CRPC.xx Despite now having received FDA approval in asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer (CRPC), it remains to be seen how frequently Provenge will be used in the treatment of this disease. At present, patients are typically treated with standard Taxotere (docetaxel; Sanofi-Aventis)-based chemotherapy. Taxotere is relatively simple in terms of manufacture and use, capable of immediate, 'off the shelf' administration. In comparison, an autologous vaccine like Provenge requires a costly and labor-intensive manufacturing process.
Dendreon has indicated that Provenge will be priced at $31,000 per dose, equating to $93,000 per complete course of treatment. In comparison, Taxotere costs under $3,000 per cycle of therapy, with an average of six cycles of treatment therefore costing around $18,000. Dendreon has stated that Provenge is more cost effective due to the lack of required premedication and supportive care costs compared to Taxotere.
Furthermore, Provenge's favorable toxicity profile may influence physician preference in comparison to Taxotere's adverse side effects, particularly in patients who are asymptomatic. Taxotere is associated with significant toxicity, while Provenge causes only mild grade 1/2 side effects. Provenge is therefore likely to be used in those patients precluded from Taxotere therapy.
Provenge's approval in asymptomatic or minimally asymptomatic patients indicates that the vaccine may be used before Taxotere. Presumably once patients progress and become symptomatic after Provenge, Taxotere will still be required. Given that healthcare systems are becoming increasingly cost-conservative, the high cost of Provenge may hinder its uptake in some patient groups, particularly those that do not qualify for the patient access plan that Dendreon has set up in light of the approval.
See also our editorial: Advaxis lights up the future for cervical cancer and maybe some head and neck cancers
Related Reports
Previous Editorials
- Pfizer just can't seem to win with Champix/Chantix as another label change approaches
- Tacrolimus as a new approach to pulmonary artery hypertension?
- As the HCV field continues to move forward all looks rosy for telaprevir but we are not so sure about boceprevir
- Telaprevir takes a leap towards the HCV market while boceprevir appears to be crawling over the line
- The patent cliff is set to drive global generic uptake despite tougher market conditions
- Dual advances in the treatment of Clostridium difficile
- FDA to decide of everolimus (Afinitor) and Sunitinib (Sutent) for the treatment of advanced pancreatic neuroendocrine tumors (PNET)
- Vandetanib is approved in the US for medullary thyroid cancer
- Clopidogrel variability - GIFT data puts the brakes on PON-1 as a major factor modifying the response to clopidogrel.
- UK recommendation for Merck's Simponi but it may struggle to make an impact in the rheumatoid arthritis market
- HPV vaccine fight against cervical cancer continues to be hampered in some parts of Europe
- Ipilimumab continues to push forward expectations for the treatment of melanoma
- Further evidence points to nicotinic receptors modifying amyloid as well as improving cognition
- Repligen reports Phase 3 RG1068 data: Improved MRI imaging of pancreatic and biliary disease expected to reduced ERCP procedures
- GSK's Avandia survives FDA panel vote but damage may have been done
- New data analysis reduces some of the concerns over upcoming Systemic Lupus Erythematosus (SLE) treatment, Benlysta (belimumab)
- APS 2010: fibromyalgia newcomer seeks differentiation while prospective player draws nearer
- NicOx: FDA panel negative opinion casts future of osteoarthritis drug into doubt
- Dendreon: landmark cancer vaccine approval but high costs may hinder uptake
- Could generic lansoprazole become the next major advance for hepatocellular cancer
- AAN 2010: new treatments address unmet needs in Alzheimer's and epilepsy
- Clavis and Clovis collaboration to tackle problem of Gemzar (gemcitabine) resistance - New hope for pancreatic and non-small cell lung cancers
- Hope for an Alzheimers breakthrough remains despite Dimebon's failure
- Agendia's MammaPrint prognostic technology: Improving medical management of breast cancer patients with small tumours
- Advaxis lights up the future for cervical cancer and maybe some head and neck cancers
- Javelin Pharmaceuticals continues to show promise in the pain arena
- Promising data reads out from ADVANCE as first generation oral HCV therapies march on